+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2021

  • ID: 5237630
  • Clinical Trials
  • September 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • AI Therapeutics
  • Altavant Sciences
  • Evergreen Therapeutics
  • Incyte Corporation
  • Incyte Corporation
  • Koutif Therapeutics
This “Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Bronchiolitis Obliterans Syndrome Understanding

Bronchiolitis Obliterans Syndrome: Overview


Bronchiolitis obliterans is also known as obliterative bronchiolitis or constrictive bronchiolitis. It is an inflammatory condition that affects the lung's bronchioles, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. The diagnosis of bronchiolitis obliterans is based on the medical history, physical examination, and various tests like imaging studies (such as a chest CT scan), pulmonary function tests, and/or surgical lung biopsy. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. Medications prescribed to patients with bronchiolitis obliterans include antibiotics (called macrolide antibiotics), corticosteroids, and immunosuppressive drugs. In severe cases, lung transplantation may be recommended.

"Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiolitis Obliterans Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans Syndrome Emerging Drugs Chapters


This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs


Liposomal Cyclosporine A: Zambon


Liposomal Cyclosporine A is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs that is administered through a drug-specific investigational nebulizer. The drug is in Phase III clinical studies for the treatment of bronchiolitis obliterans syndrome. In April 2020, the FDA had granted fast track designation to liposomal cyclosporine A for inhalation for treatment of bronchiolitis obliterans syndrome.

LAM-001: AI Therapeutics


LAM-001 is an inhaled formulation of rapamycin, which is an mTOR inhibitor. The drug is in Phase II clinical studies for the treatment of bronchiolitis obliterans syndrome and pulmonary sarcoidosis.

Bronchiolitis Obliterans Syndrome: Therapeutic Assessment


This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchiolitis Obliterans Syndrome


There are approx. 8+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.

Phases


This report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Report Insights

  • Bronchiolitis Obliterans Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
  • How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AI Therapeutics
  • Zambon
  • Incyte Corporation
  • Mereo BioPharma
  • Incyte Corporation
  • Evergreen Therapeutics
  • Altavant Sciences
  • Koutif Therapeutics

Key Products

  • LAM-001
  • Liposomal Cyclosporine A
  • Ruxolitinib
  • Alvelestat
  • Itacitinib
  • EG-004
  • ALTA 2530
  • KT-1002
This product will be delivered within 1 business day.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AI Therapeutics
  • Altavant Sciences
  • Evergreen Therapeutics
  • Incyte Corporation
  • Incyte Corporation
  • Koutif Therapeutics

IntroductionExecutive Summary
Bronchiolitis Obliterans Syndrome: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Bronchiolitis Obliterans Syndrome - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

Liposomal Cyclosporine A: Zambon
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

LAM-001: AI Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)
  • Comparative Analysis

Alvelestat: Mereo BioPharma
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

EG-004: Evergreen Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Bronchiolitis Obliterans Syndrome Key CompaniesBronchiolitis Obliterans Syndrome Key ProductsBronchiolitis Obliterans Syndrome- Unmet NeedsBronchiolitis Obliterans Syndrome- Market Drivers and BarriersBronchiolitis Obliterans Syndrome- Future Perspectives and ConclusionBronchiolitis Obliterans Syndrome Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Bronchiolitis Obliterans Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Bronchiolitis Obliterans Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AI Therapeutics
  • Zambon
  • Incyte Corporation
  • Mereo BioPharma
  • Incyte Corporation
  • Evergreen Therapeutics
  • Altavant Sciences
  • Koutif Therapeutics
Note: Product cover images may vary from those shown